Section of Hematology-Oncology, Department of Medicine, VA Nebraska Western Iowa Health Care System, Omaha, NE 68198-7680, USA.
Indian J Med Res. 2013 Jun;137(6):1043-51.
Small cell lung cancer (SCLC) has a clinical course that is distinct from its more common counterpart non-small cell lung cancer. SCLC continues to be a major clinical problem, with an aggressive clinical course and short disease-free duration after initial therapy. Current optimal treatment consists of chemotherapy with platinum-etoposide, given concurrently with thoracic irradiation in patients with limited stage disease and chemotherapy alone in those with extensive stage. Prophylactic cranial irradiation (PCI) is recommended for patients who have responded to initial therapy, as it not only decreases the risk of brain metastases and but also improves overall survival. Newer targeted agents are currently being evaluated for this disease.
小细胞肺癌（SCLC）的临床过程与更常见的非小细胞肺癌不同。SCLC 仍然是一个主要的临床问题，具有侵袭性的临床过程和初始治疗后短暂的无疾病生存期。目前的最佳治疗方法是铂类依托泊苷化疗，局限期疾病患者同时给予胸部放疗，广泛期疾病患者单独给予化疗。对于初始治疗有反应的患者，建议进行预防性颅脑照射（PCI），因为它不仅降低了脑转移的风险，而且还提高了总生存率。目前正在评估新的靶向药物用于治疗这种疾病。
